Also listed under Autoimmune Diseases
ClinicalTrials.gov term: Lupus Erythematosus, Systemic
43 trials changed in the last 30 days: 5 stopped, 16 with notable changes, 22 with minor changes only.
Trial terminated
Also in this update: Trial sites reduced: 103 → 74 locations; Study completion date changed from estimate of Sep 28, 2028 to Oct 1, 2026
Novartis PharmaceuticalsPhase 2 NCT05268289 Registry history of NCT05268289 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Final enrollment: 2 participants — 6% of the 36 planned; Study completion date changed from estimate of Apr 25, 2027 to Apr 25, 2026
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1 NCT06943937 Registry history of NCT06943937 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Terminated
Also in this update: Phase changed: not applicable → Early Phase 1; Primary completion date changed from estimate of Sep 1, 2027 to Apr 1, 2026
Base Therapeutics (Shanghai) Co., Ltd.Early Phase 1 NCT07083349 Registry history of NCT07083349 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Withdrawn
Beijing Boren HospitalPhase 1 NCT07361094 Registry history of NCT07361094 on ClinicalTrials.gov (opens the registry)
Withdrawn before enrolling
Also in this update: Primary completion date changed from estimate of Sep 20, 2028 to Sep 23, 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEarly Phase 1 NCT07583030 Registry history of NCT07583030 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 8, 2030 to Apr 3, 2034
Also in this update: Trial sites expanded: 143 → 162 locations; Study completion pushed from Apr 5, 2032 to Oct 2, 2034
Novartis PharmaceuticalsPhase 3 NCT06133972 Registry history of NCT06133972 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 29, 2030 to May 3, 2032
BiogenPhase 3 NCT05352919 Registry history of NCT05352919 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2029 to Sep 2030
Kite, A Gilead CompanyPhase 1 NCT07038447 Registry history of NCT07038447 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 7, 2024 to Jun 22, 2026
Also in this update: Trial completed
Leiden University Medical CenterPhase 3 NCT03747159 Registry history of NCT03747159 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Children's Hospital Medical Center, CincinnatiNot specified NCT07602595 Registry history of NCT07602595 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Phase 1 NCT07748156 Registry history of NCT07748156 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 1/2 → Phase 2
Also in this update: Recruitment opened; Trial sites expanded: 0 → 4 locations
iCell Gene TherapeuticsPhase 2 NCT07328581 Registry history of NCT07328581 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1 NCT07649265 Registry history of NCT07649265 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 41 → 128 locations
AstraZenecaPhase 3 NCT07691970 Registry history of NCT07691970 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 44 → 71 locations
AstraZenecaPhase 3 NCT07751848 Registry history of NCT07751848 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 32 locations
AstraZenecaPhase 2 NCT07630714 Registry history of NCT07630714 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Instituto de Investigación Sanitaria de la Fundación Jiménez DíazPhase 1/2 NCT07799116 Registry history of NCT07799116 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Primary completion pushed from Nov 2026 to Feb 2027; Study completion pushed from May 2027 to Sep 2027
Northwell HealthPhase 2 NCT06987565 Registry history of NCT06987565 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Peking University Third HospitalEarly Phase 1 NCT07301164 Registry history of NCT07301164 on ClinicalTrials.gov (opens the registry)
Start date pushed from Oct 10, 2026 to Nov 19, 2026
PfizerPhase 1/2 NCT07782450 Registry history of NCT07782450 on ClinicalTrials.gov (opens the registry)
Trial completed
Novartis PharmaceuticalsPhase 1/2 NCT05798117 Registry history of NCT05798117 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 2025 to Oct 27, 2025; Final enrollment: 125 participants (planned 157)
Kyowa Kirin Co., Ltd.Phase 1 NCT05411016 Registry history of NCT05411016 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 149 participants (planned 90)
Sohag UniversityNot specified NCT06796569 Registry history of NCT06796569 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 2026 to Dec 2026
Also in this update: Study completion pushed from Sep 2026 to Mar 2027
Ventus Therapeutics U.S., Inc.Phase 2 NCT07260877 Registry history of NCT07260877 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jun 1, 2027 to Sep 21, 2026
National Center for Complementary and Integrative Health (NCCIH)Not specified NCT03952624 Registry history of NCT03952624 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jun 2026 to Oct 21, 2025; Final enrollment: 325 participants (planned 500)
Institut National de la Santé Et de la Recherche Médicale, FranceNot specified NCT04902807 Registry history of NCT04902807 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Also in this update: Study completion pushed from Oct 2026 to Sep 1, 2027; Primary completion date changed from estimate of Apr 2026 to Jun 15, 2026
Second Xiangya Hospital of Central South UniversityNot applicable NCT07104344 Registry history of NCT07104344 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Tongji HospitalEarly Phase 1 NCT07339540 Registry history of NCT07339540 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 36 → 57 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07355218 Registry history of NCT07355218 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 45 → 60 locations
EMD Serono Research & Development Institute, Inc.Phase 3 NCT07332481 Registry history of NCT07332481 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 119 → 123 locations
UCB Biopharma SRLPhase 3 NCT04976322 Registry history of NCT04976322 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 249 → 260 locations
Janssen Research & Development, LLCPhase 3 NCT07438496 Registry history of NCT07438496 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 2027 to Sep 2029
University of Alabama at BirminghamNot applicable NCT07716462 Registry history of NCT07716462 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 2026 to Jan 2027
Mayo ClinicPhase 2 NCT04868838 Registry history of NCT04868838 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
RemeGen Co., Ltd.Phase 2 NCT05680480 Registry history of NCT05680480 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Bioray LaboratoriesEarly Phase 1 NCT06681337 Registry history of NCT06681337 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Bioray LaboratoriesNot applicable NCT05988216 Registry history of NCT05988216 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Universitas PadjadjaranPhase 2/3 NCT06618573 Registry history of NCT06618573 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Assiut UniversityNot specified NCT06601361 Registry history of NCT06601361 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Meyer Children's Hospital IRCCSNot applicable NCT06586710 Registry history of NCT06586710 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Assiut UniversityNot specified NCT06586359 Registry history of NCT06586359 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Tongji HospitalNot specified NCT06458972 Registry history of NCT06458972 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-09 | NCT07868289 Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus… | Istanbul University - Cerrahpasa new | |
| 2026-09-28 | NCT07844200 The Primary Objective of the Trial is to Evaluate the Effect of the Addition of… | Medical Association for the Study of Cancer Biology and Treatment new | Phase 2 |
| 2026-09-25 | NCT07840573 Feasibility and Performance of a Structured Video Telemedicine Program in Patients With… | Baylor College of Medicine new | |
| 2026-09-21 | NCT07829614 F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus… | Shandong New Time Pharmaceutical Co., LTD new | Phase 1 |
| 2026-09-02 | NCT07799116 Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy… | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz new | Phase 1/2 |
| 2026-08-25 | NCT07783711 Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus… | Khaled Samir Malak Nashed new | |
| 2026-08-24 | NCT07783269 A Basket Study of CTA313 in Participants With Active Autoimmune Diseases | Imviva Bio new | Phase 1 |
| 2026-08-21 | NCT07778446 A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics new | Phase 1/2 |
| 2026-08-18 | NCT07771088 Exploring Biological Mechanisms Underlying the TEACH Intervention for Adolescents With… | The Hospital for Sick Children new | |
| 2026-08-17 | NCT07767188 A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active… | Zhao Minghui new | Phase 3 |
| Early Phase 1 | 39 | |
| Phase 1 | 114 | |
| Phase 1/2 | 46 | |
| Phase 2 | 63 | |
| Phase 2/3 | 4 | |
| Phase 3 | 41 | |
| Phase 4 | 20 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06594068 | Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in… | AstraZeneca | Recruiting | 2026-09-16 |
| NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic… | Bristol-Myers Squibb | Recruiting | 2026-09-09 |
| NCT07760480 | Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months… | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting | 2026-08-12 |
| NCT07611214 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients… | Aurinia Pharmaceuticals Inc. | Recruiting | 2026-08-03 |
| NCT07719140 | Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT… | Peking Union Medical College Hospital | Recruiting | 2026-07-22 |
| NCT07087912 | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in… | University of Sao Paulo General Hospital | Recruiting | 2026-07-20 |
| NCT07700940 | The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population | Ahmed Yehia Ismail | Recruiting | 2026-07-15 |
| NCT03543839 | Trial of Belimumab in Early Lupus | Northwell Health | Recruiting | 2026-06-12 |
| NCT07611747 | Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in… | Instituto de Investigación Marqués de Valdecilla | Recruiting | 2026-05-28 |
| NCT07323524 | Dapagliflozin in Active Lupus Nephritis | Brigham and Women's Hospital | Recruiting | 2026-05-26 |
| NCT07077486 | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease | Tongji Hospital | Recruiting | 2026-01-27 |
| NCT05559671 | Safety of the Herpes Zoster Subunit Vaccine in Lupus | NYU Langone Health | Recruiting | 2025-12-26 |
| NCT07225387 | Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of… | NephroNet, Inc. | Recruiting | 2025-11-06 |
| NCT05207358 | Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis | Institutul Clinic Fundeni | Recruiting | 2022-03-03 |
| NCT06411249 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult… | GlaxoSmithKline | Active, Not Recruiting | 2026-09-01 |
| NCT07381465 | Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus | Chinese SLE Treatment And Research Group | Active, Not Recruiting | 2026-07-15 |
| NCT05879419 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | University of Sao Paulo General Hospital | Active, Not Recruiting | 2026-05-04 |
| NCT07035834 | SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis… | Federico II University | Not Yet Recruiting | 2025-06-25 |
| NCT06763783 | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases | Region Skane | Enrolling by Invitation | 2025-01-10 |
| NCT06677801 | Immune Cell Subsets in SLE Patients Treated with Telitacicept | Second Affiliated Hospital, Zhejiang University, School of Medicine | Active, Not Recruiting | 2024-11-07 |
| Phase 3 | ||||
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants… | UCB Biopharma SRL | Recruiting | 2026-10-15 |
| NCT06133972 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With… | Novartis Pharmaceuticals | Recruiting | 2026-10-13 |
| NCT06711887 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study… | Novartis Pharmaceuticals | Recruiting | 2026-10-13 |
| NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | EMD Serono Research & Development Institute, Inc. | Recruiting | 2026-10-06 |
| NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | EMD Serono Research & Development Institute, Inc. | Recruiting | 2026-10-06 |
AstraZeneca (26) · Assiut University (25) · The Children's Hospital of Zhejiang University School of Medicine (11) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (11) · Novartis Pharmaceuticals (8) · Assistance Publique - Hôpitaux de Paris (7) · Bristol-Myers Squibb (7) · Chinese SLE Treatment And Research Group (7) · Sohag University (7) · Beijing GoBroad Hospital (6)